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GeneticsAn innovative approach to the therapy of essential hypertension (EH) and the related complications has
been pursued by our group with the aim of deﬁning speciﬁc genetic-molecular mechanisms underlying the
disease in sub-sets of patients. This approach is anticipated to have a major effect on the clinical practice,
diagnostics and development of new drugs able to selectively target such mechanisms. The ﬁnal achieve-
ment is the deﬁnition of biomarkers for identifying patients who more likely should beneﬁt for a given
therapy both in terms of efﬁcacy and reduction of the adverse reactions. Among many, two mechanisms have
been deﬁned and addressed:
1) polymorphisms in the gene coding for the cytoskeletal protein, adducin;
2) increased levels of the salt and blood pressure-regulating hormone, endogenous ouabain (EO).
Both alterations lead to hypertension, organ hypertrophy, negative vascular remodeling and increased
cardiovascular risk by affecting the renal Na+ handling, through the up-regulation of the Na+–K+ pump and
the activation of the Src-dependent signal transduction pathway. A novel antihypertensive agent,
rostafuroxin (PST2238), has been selected and developed for its ability to correct the renal Na+–K+ pump
abnormalities sustained by the mutant adducin and EO-dependent mechanisms. It is endowed with high
potency and efﬁcacy in reducing blood pressure (BP) and preventing organ hypertrophy in animal models
representative of both adducin and EO mechanisms. At molecular level, in the kidney, rostafuroxin
normalizes the enhanced activity of the Na+–K+ pump induced by mutant adducin and antagonizes the EO
triggering of the Src-EGFr-dependent signaling pathway leading to renal Na+–K+ pump and ERK
phosphorylation and activation. In the vasculature, it normalizes the increased myogenic tone caused by
ouabain. A very high safety ratio and the absence of interaction with other mechanisms involved in BP
regulation, together with evidence of high tolerability and efﬁcacy in hypertensive patients indicate
rostafuroxin as the ﬁrst example of a new class of antihypertensive agents designed to antagonize adducin
and EO-hypertensive mechanisms. A recently concluded Phase II clinical trial (OASIS) has provided the proof
of concept that such a compound is effective in the subset of patients where these two mechanisms are at
work.ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Primary hypertension is a complex polygenic disorder affecting 30–
40% of the adult population in the industrialized countries and
representing the major determinant for cardiovascular (CV), renal
and cerebral organcomplications [1]. The interactionbetweencommon
genetic variants and environment unmasks the disease through the
modulation of renal, vascular, nervous and hormonal functions [2]. This
complexity accounts for the poor understanding of the speciﬁc
mechanisms of hypertension and also for the marked variability inthe individual response to the therapy [3,4]. It is calculated that only
one third of patients who are aware on their hypertensive status have
their blood pressure (BP)well controlled [5,6]. Amongmany reasons of
this failure (poor efﬁcacy, low compliance, adverse side effects), a
prominent one concerns the lack of knowledge of the genetic-
molecular basis of BP control. Deﬁning the genetic-molecular mechan-
isms underlying different forms of hypertension and associated organ
complications is needed to target treatments to the characteristics of
the patient and optimize their response to the therapy [7–9].
Among many functional alterations, it is well established that the
impairment of the pressure-natriuresis mechanism leading to salt
retention and elevated peripheral resistance is a landmark of hyper-
tension development [10–13]. This ﬁnding has been consistently
conﬁrmed both in animal models of genetic hypertension [10,14] and
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basolateral side of the renal tubuli, is the driving force for renal
sodium reabsorption. Any mechanism altering the Na+–K+ pump
function/expression may therefore be candidate for hypertension
pathogenesis and represents a potential new therapeutic target [16].
During the last 20 years, studies spanning from the whole body to
the gene level, let us to contribute at clarifying the clinical impact of
two mechanisms that, by affecting the renal Na+–K+ pump function,
are associated to hypertension in rats and humans:
a) the endogenous ouabain (EO), a salt modulating hormone, whose
circulating levels are under a genetic control [17–19];
b) the polymorphism of the genes encoding for the cytoskeletal
protein adducin [20–22].
There is considerable evidence that supports the clinical impact of
these two genetic-molecular mechanisms on hypertension and
related organ complications [23–27]. Two other chapters in this
issue [28,29] are speciﬁcally dedicated to detail such evidence. Here,
we report only a summary of the peculiarities of these mechanisms.
Ouabain/EO levels associate to BP and CV complications both in
rats infused with ouabain [24] and in humans suffering from early and
mild to long-lasting and more severe hypertension [19,25–27], thus
indicating the primacy of EO in causing cardiac damage. The patho-
physiological consequences of EO level alterations have been recently
attributed to the ability of low ouabain concentrations to trigger
the Na+,K+ATPase-Src-ERK1/2-dependent signaling in caveolae and
to determine the up-regulation of the renal Na+–K+ pump activity
and the expression of growth-related genes [24,30–32]. In addition,
evidence has been reported indicating on how EO/ouabain, beside its
renal effects, increases the myogenic tone of small resistance arteries,
thus contributing to a sustained increase of BP through the increase of
total peripheral resistance [33].
Adducin is a cytoskeletal protein, formed by three isoforms (α, β
and γ), which participates in many cellular processes such as actin
polymerization, cell volume and ion transport regulation, cell-to-cell
contact, control of the residential time of integral membrane pro-
teins (Na+–K+ATPase, Integrins), calcium handling and signal trans-
duction [34,35,36, Ferrandi M., personal communication). The role of
α-adducin polymorphisms on rodent (F316Y) and human (G460W)
hypertension and associated CV risk has been widely documented
and demonstrated to be dependent from the genetic and environ-
mental context [23,28]. Studies aimed at clarifying the molecular
mechanisms through which adducin polymorphisms affect BP and
organ complications have indicated that mutant α-adducin variants
increase renal Na+–K+ATPase activity and expression through a
direct interaction between adducin and the Na+–K+ATPase [37].
More recently, a selective activation of the Na+–K+ATPase-Src-
dependent signaling induced by the mutant α-adducin has been
documented in renal caveolae of congenic rats (MHS.H-Add1),
carrying the mutant α-adducin locus (Add1) introgressed from the
Milan Hypertensive rat strain (MHS) into the Milan Normotensive
rat strain (MNS) background (Ferrandi M., personal communica-
tion). This suggests that mutant adducin may alter the Na–K pump
function and the expression of growth-related genes involved in
CV complication, through molecular mechanisms having similar
features as those described for the EO/ouabain.
These ﬁndings have then been used to address two objectives:
1) to develop a new therapeutic intervention able to target the altered
molecular mechanisms triggered by EO and adducin mutations,
and 2) to identify biomarkers for selecting essential hypertensive
patients who are likely to successfully respond to the new therapeutic
intervention.
In this respect, the enhanced activity of the renal Na+–K+ATPase
triggered bymutant adducin and EO and the Src-dependent activation
of signal transduction induced by EO represent new pharmacological
targets for a tailored antihypertensive therapy. Moreover, the geneticproﬁle underlying such altered mechanisms may represent the
biomarker/s for identifying the patients prone to be cured with the
new therapy.
Based on this, our group developed a new comprehensive line
of research which led to the identiﬁcation of a number of original
compounds with antihypertensive properties, being able to antago-
nize the hypertensive effect and the molecular alterations induced by
EO (or ouabain) or adducin polymorphism, without interfering with
other known physiological mechanisms.
Among the compounds studied, a novel antihypertensive agent
rostafuroxin (PST2238), has been selected in preclinical studies for its
ability to selectively correct the molecular alterations sustained by
adducin mutations and EO [38]. Its pharmacological proﬁle and the
mechanism of action will be summarized in the present review.
Furthermore, the pharmacogenomic strategy adopted for testing the
clinical efﬁcacy of rostafuroxin in subset of patients carrying the




14beta, 17alpha-triol-hydrate) is a digitoxigenin derivative that dis-
places ouabain binding from the dog kidney Na+–K+ATPase with an
IC50 of 2 μM without interfering with other receptors or enzymatic
activities known to be involved in the BP regulation or hormonal
steroid control [39].
Its ability to counteract the molecular effects of EO/ouabain and
mutant α-adducin on the Na+–K+ pump function has been proved in
cultured renal cells either exposed to nanomolar ouabain for a long-
term [39] or transfected with the mutant α-adducin variants [40]. In
both conditions, the Na+–K+ pump activity is signiﬁcantly increased
as compared with the respective control cells and rostafuroxin is able
to normalize it to the physiological levels, at concentrations ranging
from 10−10 to 10−8 M, without altering the Na+–K+ pump activity in
control cells [39,40] (Fig. 1).
The efﬁcacy and potency of rostafuroxin in antagonizing the EO
and mutant α-adducin hypertensive effects have been also proved in
“in vivo” rat models carrying speciﬁc forms of hypertension. Ouabain
increases BP in Sprague Dawley rats when infused at very low
doses (15 μg/kg/day) for 4–8 weeks (OS rats) [39]. This hypertensive
effect is paralleled by an increased function and expression of the
renal Na+–K+ pump [24,39] and, in the long run, by left ventricle and
renal hypertrophy [24]. All of these ouabain-dependent effects are
prevented by chronic administration of rostafuroxin at oral doses
ranging from 0.1 to 10 μg/kg [24,39] Fig. 1. The ability of rostafuroxin
to antagonize the hypertensive effect of ouabain was also observed on
the vascular bed. The increased contractile response of mesenteric
arteries isolated from OS rats to 75 mM extracellular KCl is completely
normalized by a 4-week treatment of OS rats with 100 μg/kg os
rostafuroxin [41]. Moreover, it has been demonstrated that the
increase of mouse mesenteric artery myogenic tone caused by “in
vitro” exposure to ouabain, is completely antagonized by rostafuroxin
[33]. The involvement of EO in volume-dependent forms of hyper-
tension is supported by data obtained in different experimental
models [18,38,42] and also in humans [19,26,27]. Rostafuroxin dis-
plays a clear antihypertensive effect in these forms of volume-depen-
dent hypertension such as DOCA-salt and Reduced-Renal-Mass
hypertensive rats [38,42], while no activity is observed in SHR and
normotensive animals [42].
The Milan strain of spontaneously hypertensive rats (MHS) is
an animal model in which mutations on the α-adducin [20] and
increased EO levels [17] are associated to hypertension, cardiac hy-
pertrophy and increased expression and function of the renal Na+–K+
pump [24]. Rostafuroxin reduces BP and cardiac hypertrophy in MHS
rats [40] and in parallel normalizes their Na+–K+ pump activity [40]
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several weeks (ED50=4 μg/kg os) (Fig. 1).
The antihypertensive activity of rostafuroxin is long-lasting since it
is still present 24 h after oral treatment [40].
Despite its digitoxigenin-like structure, rostafuroxin is devoid of
any digitalis-like cardiac effect in intravenously treated guinea pigs
up to 6.7 mg/kg i.v. [42].
2.1. Molecular mechanisms
Studies aimed at characterizing themolecularmechanism of action
of this novel agent are in progress. The available data show that
rostafuroxin is able to normalize the alterations of the Na+–K+ATPase
trafﬁcking affected by both ouabain and mutant adducin [35].
Furthermore, the effect of rostafuroxin on the ouabain-dependent
hypertensive and pro-hypertrophic cardiac and renal effects has been
recently elucidated [24]. In specialized membrane districts, the caveolae,
where signal transductionproteins are clustered, sub-nanomolarouabain
concentrations induce the enrichment of Na+–K+ATPase isoforms, Src
and EGFr signaling molecules [24]. This process leads to the activation of
the membrane Na+–K+ATPase and ERK1/2 in the cytosol thus favoring
the increase of trans-epithelial Na+ transport and the transcription of
growth-related genes in the nucleus [45]. Rostafuroxin, by speciﬁcally
displacingouabainbinding fromthehighafﬁnityNa+–K+ATPase isoform
present in the caveolae, antagonizes all theouabain functional effects [24]
(Fig. 1).
Similarly to what was observed for the ouabain-dependent molec-
ularmechanism, it has been recently demonstrated that adducins (both
from the rat model and humans) interact with the Na+–K+ATPase-Src-Fig. 1. Summary of the activities of rostafuroxin in different preclinical experimental settings
adducin mutation (Milan hypertensive strain, MHS) or altered circulating levels of ouabain/end
pressureandnormalizes theup-regulated renalNa+–K+ATPase functionboth inMHSandOS rat
(NRK) either stably transfectedwith the rat mutantα-adducin variant (NRK-1) or incubatedwi
activity atVmaxas comparedwith the respective controls cells (NRKexpressing thewild typeα-
the Na+–K+ATPase activity at Vmax, without affecting the pump activity in control cells, at co
either mutantα-adducin variant or 10−9 M ouabain signiﬁcantly increase the Src-dependent T
control conditions: rostafuroxin nulliﬁes both the difference between the mutant and wild t
signaling pathway, at concentrations ranging from 10−9 to 10−11 M [24, Ferrandi M., personadependent signaling pathway, triggering its activation in renal caveolae
(Ferrandi M., personal communication). This interaction is however
different for the mutant adducin variants as compared with the normal
ones causing a further activation of the Src-dependent signaling which
induces an increase of the Na+–K+ATPase tyrosine phosphorylation
and activity. In several experimental settings (MHS.H-Add1 congenic
rats, cultured renal cells transfected with the human adducin variants,
cell-free system with recombinant adducins and Src), rostafuroxin
completely antagonizes the molecular effects of the mutant but
not of the normal adducin variants, normalizing the triggering of the
Na+–K+ATPase-Src-dependent signal transduction pathway at con-
centrations ranging from 10−10 to 10−11 M (Ferrandi M., personal
communication) (Fig. 1). The functional consequence of this molecular
mechanism is a selective normalization of the Src-dependent signaling
and reduction of the up-regulated renal Na+–K+ATPase activity (Fig. 1).
Consequently, a reduction of the tubular Na+ reabsorption is expected
in those subjects carrying the mutant adducin variants.
2.2. Safety and tolerability
Rostafuroxin is characterized by a highly safe proﬁle, as indicated
by acute and chronic toxicological and pharmacological safety studies.
Acute oral toxicity of rostafuroxin in rats yields LD50>2000 mg/kg
[42]. Chronic toxicological studies, performed in rats and monkeys,
indicate a NOAEL (no observed adverse effect level) of 250 μmol/kg/
day os for rats and 450 μmol/kg/day os for monkeys [42]. Therefore,
at least in rats, the ratio between the effective antihypertensive and
the toxic dose appears to be higher than 1 to 10,000, considering
an oral effective doses ranging from 0.25 to 25 nmol/kg/day [42].: a) “in vivo” animal models representative of forms of hypertension sustained either by
ogenous ouabain (EO) (ouabain infused rats, OS): rostafuroxin signiﬁcantly reduces blood
s atoral doses of 1–10and0.1–1 μg/kg/day, respectively [38–40]; b) cultured rat renal cells
th 10−9 M ouabain for 5 days (NRK-E) display a signiﬁcant increase of the Na+–K+ATPase
adducinvariant orNRK incubatedonlywithmedium): rostafuroxin completelynormalizes
ncentrations ranging from 10−9 to 10−11 M, respectively [38–40]. c) in “cell-free system”
yr phosphorylation of the renal Na+–K+ATPase and ERK, as compared with the respective
ype α-adducin and the ouabain-dependent triggering mechanism of the Src-dependent
l communication].
Table 1
Comparison between therapeutic “traditional approach” (one drug in the general
patient population) with the “present approach” (one speciﬁc drug in a population
selected by genotyping).
Traditional Present
SBP fall by a single drug
(placebo-corrected effect)
6–12 mm Hg 14–23 mm Hga
Difference in SBP fall among single drugs None or −3 mm Hg 5–12 mm Hga
Reduction of CV complications
(vs. placebo)
∼20% Expected >20%b
a Depending upon the composition of the genetic proﬁle.
b Due to the larger BP fall and rostafuroxin effect on the speciﬁc mechanisms
underlying CV complications.
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pharmacological safety proﬁle [42]. Although a component of the
antihypertensive activity of rostafuroxin is linked to its ability to
normalize the increased tubular Na+ transport, as stated above, it is
completely devoid of any diuretic activity either after acute or chronic
treatments [43]. As consequence, rostafuroxin does not cause the
typical diuretic's side effects such as activation of the Renin–
Angiotensin–Aldosterone (RAA) system, hypokalemia, alterations of
lipidic and glucidic proﬁles.
2.3. Clinical studies
Phase I clinical studies conﬁrmed the safety of rostafuroxin also in
healthy volunteers after both single and repeated administrations
[38].
Two explorative small Phase II clinical trials aimed at testing the
antihypertensive efﬁcacy and tolerability of rostafuroxin in mild
essential hypertensive patients, have conﬁrmed the safety of the drug
and its ability to lower BP at the low oral doses ranging from 0.1 to
1 mg/day [38].
A Phase II Europeanmulticentric, dose-range ﬁnding, clinical study
on 440 patients withmoderate, uncomplicated essential hypertension
was recently concluded [44]. The primary end-points were aimed at
identifying the effective doses on systolic and diastolic BP fall, both as
ofﬁce and 24-h BP measurements. The inﬂuence of the variations
within the genes coding for adducin isoforms (ADD1, ADD2 and
ADD3) and some enzymes involved in EO synthesis and metabolism
(LSS, MDR2, HSD) on the magnitude of BP fall after rostafuroxin was
also included as secondary end point [44]. A wide genome scanning
(WGS), using the Illumina technology on 1 million SNPs for each
patient, has been performed. The analysis of these data allowed us to
identify a deﬁned subset of patients carrying speciﬁc combinations of
these genetic variants whose BP was normalized by rostafuroxin
at nanomolar oral doses and unaffected by placebo. Based on the
available data, we may predict that the clear separation would occur
in at least 20–25% of hypertensive patients. This ﬁnding is consistent
with the preclinical evidence of the adducin and/or EO-mediated
activation of signaling pathways associated with hypertension and
related organ complications. Moreover, it supports the pharmacoge-
nomic strategy by which rostafuroxin has been developed as the ﬁrst
example of a novel antihypertensive agent targeted to patients
carrying speciﬁc genetic ﬁngerprints.
When this strategy is compared with the traditional therapeutic
approach where one antihypertensive drug should be effective in the
whole hypertensive population, the advantages in terms of improve-
ment of efﬁcacy, safety and reduction of the healthy costs are evident.
From an overview of the available literature (see Table 1), it emerges
that the systolic BP fall induced by a single antihypertensive drug
(either diuretics or Angiotensin Converting Enzyme (ACE) inhibitors
or Angiotensin Receptor Blockers (ARBs) or renin inhibitors, etc.)
ranges from 6 to 12 mm Hg, when corrected for the placebo effect
[46–50]; moreover, the difference in terms of efﬁcacy among thedifferent classes of drugs is no more higher than 3 mm Hg and the
organ complication reduction does not exceed the 20% [51]. The data
obtained in the OASIS study on the efﬁcacy of rostafuroxin in a
selected, genotyped population indicate an improved efﬁcacy both
with respect to placebo and a traditional antihypertensive agent.
Moreover, the targeting and correction of the altered mechanisms
responsible for the disease are in keeping with an improved control of
the organ complications and a consequent reduction of the health
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